Italia markets close in 5 hours 12 minutes

Vericel Corporation (VCEL)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
46,94-0,89 (-1,86%)
Alla chiusura: 04:00PM EDT
46,94 0,00 (0,00%)
Dopo ore: 04:01PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente47,83
Aperto48,00
Denaro46,79 x 100
Lettera47,02 x 100
Min-Max giorno46,75 - 48,41
Intervallo di 52 settimane30,18 - 53,05
Volume490.976
Media Volume431.718
Capitalizzazione2,271B
Beta (5 anni mensile)1,73
Rapporto PE (ttm)N/D
EPS (ttm)-0,07
Prossima data utili08 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A53,90
  • GlobeNewswire

    Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

    Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care Results demonstrate that NexoBrid is safe and well-tolerated without deleterious effects on wound closure and scarring CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and s

  • GlobeNewswire

    Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

    Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid launch significantly expands the total addressable market for Vericel Burn Care CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S. commercial availability of

  • GlobeNewswire

    Vericel to Present at the Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http